Loading provider…
Loading provider…
Infectious Disease Physician in Thousand Oaks, CA
NPI: 1215025291Primary Employer
Mark H Mazur MD & Barry Statner MD a Professional Corporation
HQ Phone
Get MD Ramesh's Phone Numberphone_androidMobile
Get MD Ramesh's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2002 - 2025

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Infectious Disease
UCLA David Geffen School of Medicine/UCLA Medical Center
Fellowship • Infectious Disease
2003 - 2005
Cedars-Sinai Medical Center
Residency • Internal Medicine
2000 - 2003
The George Washington University
B.S. • Chemistry
1993 - 1996
George Washington University School of Medicine and Health Sciences
smhs.gwu.edu
Medical School
Until 2000
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 408 | 1,577 |
| 2 | 99223Initial hospital inpatient care, typically 70 minutes per day | 258 | 280 |
| 3 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 170 | 323 |
| 4 | 99213Established patient office or other outpatient visit, typically 15 minutes | 161 | 289 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 79 | 87 |
Ceftolozane/Tazobactam For Treatment of Gram negative infections
Authors: Sorbera, Maria, Chung, Elizabeth, Ho, Christopher W, Marzella, Nino
Journal: P T
Lead Sponsor: Matthew Neal MD
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Intervention / Treatment: DRUG: SGLT2 inhibitor, DRUG: theraputic heparin, DRUG: prophylactic heparin, DRUG: P2Y12, DRUG: Crizanlizumab Injection
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators: Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Brii Biosciences Limited, Sagent Pharmaceuticals, Synairgen Research Ltd., SAb Biotherapeutics, Inc.
Intervention / Treatment: DRUG: Camostat, BIOLOGICAL: bamlanivimab 700mg, DRUG: Placebo for SAB-185 (high dose), BIOLOGICAL: bamlanivimab 7000mg, BIOLOGICAL: BRII-196+BRII-198, BIOLOGICAL: AZD7442 (IV), BIOLOGICAL: AZD7442 (IM), DRUG: SNG001, BIOLOGICAL: BMS-986414 + BMS-986413, BIOLOGICAL: SAB-185 (3,840 Units/kg), BIOLOGICAL: SAB-185 (10,240 Units/kg), DRUG: CASIRIVIMAB + IMDEVIMAB, DRUG: Placebo for Bamlanivimab 7000mg, DRUG: Placebo for Bamlanivimab 700mg, DRUG: Placebo for BRII-196+BRII-198, DRUG: Placebo for SNG001, DRUG: Placebo for Camostat, DRUG: Placebo for SAB-185 (low dose), DRUG: Placebo for BMS-986414 + BMS-986413, DRUG: Placebo for AZD7442 (IV), DRUG: Placebo for AZD7442 (IM)
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Donanemab